# ALLURION TECHNOLOGIES, INC. (ALURW) — merger/scheme_of_arrangement [completed]
Source: SEC API (secapi.ai) · situation sit_87eaa06dd780fe1eb536 · retrieved 2026-08-11T15:50:03.899Z

## Overview
Allurion Technologies, Inc. is a medical device company that develops gastric balloon systems for weight loss.

On July 21, 2026, Allurion Technologies, Inc. entered into an exchange agreement with RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., RTW Biotech Opportunities Operating Ltd., and 4010 Royalty Investments ICAV, whereby the stockholders exchanged an aggregate of 392,766 shares of common stock for pre-funded warrants to purchase an aggregate of 392,766 shares of common stock. The warrants have an exercise price of $0.0001 per share and are subject to a beneficial ownership limitation initially set at 9.99% of the Company's outstanding common stock (adjustable by the holder up to a maximum of 19.99% upon 61 days' prior written notice). The warrants automatically terminate upon the earliest to occur of: (i) foreclosure by the holders of the Company's Revenue Interest Financing Agreements and 6% Convertible Secured Notes due 2031, (ii) the Company's commencement of a voluntary bankruptcy case under Chapter 7 or Chapter 11, or (iii) the holder's election to terminate the warrant. The exchange was consummated on July 21, 2026, in reliance on Section 3(a)(9) of the Securities Act of 1933.

## Terms
- Counterparty: RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., RTW Biotech Opportunities Operating Ltd., and 4010 Royalty Investments ICAV · Consideration: stock · Price/share: $0.0001

## Key dates
- Completed 2026-07-21

## Timeline
- 2026-07-24 · 8-K (0001193125-26-316202): 8-K - ALLURION TECHNOLOGIES, INC. — *Allurion Technologies, Inc. is a medical device company that develops gastric balloon systems for weight loss.* On July 21, 2026, Allurion Technologies, Inc. entered into an exchange agreement with RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., RTW Biotech Opportunities Operating Ltd., and 4010 Royalty Investments ICAV, whereby the stockholders exchanged an aggregate of 392,766 shares of common stock for pre-funded warrants to purchase an aggregate of 392,766 shares of common stock. The warrants have an exercise price of $0.0001 per share and are subject to a beneficial ownership limitation initially set at 9.99% of the Company's outstanding common stock (adjustable by the holder up to a maximum of 19.99% upon 61 days' prior written notice). The warrants automatically terminate upon the earliest to occur of: (i) foreclosure by the holders of the Company's Revenue Interest Financing Agreements and 6% Convertible Secured Notes due 2031, (ii) the Company's commencement of a voluntary bankruptcy case under Chapter 7 or Chapter 11, or (iii) the holder's election to terminate the warrant. The exchange was consummated on July 21, 2026, in reliance on Section 3(a)(9) of the Securities Act of 1933.
  https://www.sec.gov/Archives/edgar/data/1964979/0001193125-26-316202.txt

## Citations
- 0001193125-26-316202 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526316202